Genmab appoints Matt Kiely as General Manager for the United Kingdom

Local Media Release – United Kingdom

Copenhagen, Denmark – September 1, 2025

• Matt Kiely joins Genmab as the company strengthens its commercialization capabilities in Europe and prepares to bring its innovative antibody-based medicines to more patients
• Matt brings more than 20 years of global pharmaceutical leadership, with deep expertise in oncology, market access, and building high-performing organizations
• With registered headquarters in Copenhagen and operations internationally, Genmab is strengthening its footprint in the UK as part of its broader commercial expansion in Europe

Genmab A/S (Nasdaq: GMAB) today announced the appointment of Matt Kiely as the General Manager for the United Kingdom as the company expands its presence in Europe to bring its innovative antibody-based medicines to more patients with cancer.

Founded in 1999 in Copenhagen, Genmab is an international biotech company that specializes in antibody-based science. As part of the company’s expansion into commercial markets in Europe, Genmab is now establishing its presence in the United Kingdom with the appointment of Matt Kiely as General Manager. In this role, Matt will lead the UK business operations, ensuring the success of future product launches and supporting Genmab’s mission to bring innovative medicines to more patients. He joins Genmab on September 1.

"Welcoming Matt to our team is a significant step in our mission to bring innovative medicines to more patients around the world. His outstanding track record in building high-performing organizations and launching successful cancer therapies makes him the ideal leader to drive our expansion in the UK, ensuring that we can deliver on our goal to bring treatments to patients in need,” said Brad Bailey, Executive Vice President and Chief Commercial Officer.

Matt joins Genmab with more than 20 years of industry experience, with a specialty in oncology and hematology. He has held senior leadership positions at companies including GSK, Takeda and Stemline Therapeutics where he was responsible for establishing and building the company’s commercialization organization in Europe. His strong track record building high-performing teams, successfully launching medicines and delivering innovative market access strategies spans geographies.

"Throughout my career, I have been passionate about oncology innovation and am excited to join Genmab, a company at the forefront of antibody science and with a strong commitment to putting patients first,” said Matt Kiely. “The UK healthcare environment holds potential for Genmab to make a difference for patients. I look forward to working with our teams to grow a strong organization and deliver on our shared vision.”

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO^®) antibody medicines. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:

Caitlin Craparo, Senior Director, Commercialization Communications
T: +1 609 255 7397; E: cacr@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations 
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®